pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
308
stories
21d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
21d
Biogen CEO tells analysts he’s focused on early-stage R&D as ‘we were not very good with that’
fiercebiotech
22d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
22d
GSK predicts ‘some limited impact’ to UK roles as restructuring rolls on
fiercebiotech
22d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
22d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
22d
Behind the scenes of 3 Big Pharma layoffs
biospace
22d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
23d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
23d
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
fiercebiotech
24d
ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug
fiercebiotech
25d
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
fiercebiotech
25d
ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss
fiercebiotech
26d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
26d
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
fiercebiotech
27d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
28d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
28d
As H-1B visa changes keep coming, biopharmas adjust hiring approach
biospace
28d
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
fiercebiotech
28d
Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapy
fiercebiotech
28d
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
fiercebiotech
28d
Astellas links up with AI Proteins in $400M computational drug discovery deal
fiercebiotech
29d
Opinion: Your company isn’t paying you what you’re worth
biospace
Oct 20, 26
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
fiercebiotech
Oct 20, 26
AstraZeneca taps Oracle to help improve recruitment for clinical trials
fiercebiotech
Oct 19, 26
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
Oct 19, 26
Merck KGaA makes noise in hematology with $1.1B Silence buy
biospace
Oct 19, 26
Roche returns to Hansoh with broad $15B ADC deal
biospace
Oct 19, 26
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
fiercebiotech
Oct 19, 26
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
fiercebiotech
← prev
page 3 of 11
next →